Lapatinib and Colchicine: Interaction Details

Brand names
Lapatinib
Tykerb
Colchicine
ColcrysGloperbaMitigare +1 more
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Colchicine

Brand names
  • Colcrys
  • Gloperba
  • Mitigare
  • Lodoco

What Happens When You Take Lapatinib With Colchicine

What can happen when they are taken together (rated Contraindicated)

Increased colchicine exposure and an increased risk of colchicine toxicity

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Colchicine must not be given together with (for example, rifampin) in patients who have established atherosclerotic disease or multiple cardiovascular risk factors and who take 0.5 mg once daily, since life-threatening and fatal colchicine toxicity has been reported in such patients even at therapeutic colchicine doses.1 The combination is likewise when colchicine is used for gout prophylaxis and treatment in patients with or impairment.2

Dose adjustments for other patient populations, indications, and/or dosage regimens are described under Quick Answers - Dose Adjustments in the colchicine monograph. To lower the risk of adverse events from colchicine drug interactions, one can substitute an alternative therapy for the interacting drug, hold colchicine while the interacting drug is in use, or, when the two drugs must be given together, decrease the colchicine dose.3

Rifampin acts as both a P-gp and a P-gp . Its early effect is , but with repeated dosing the inhibitory effect wanes and its inducing effect becomes dominant.4

The Lapatinib and Colchicine Interaction, Explained

Lapatinib can raise the level of colchicine in your body. Lapatinib blocks a cell "pump" () that helps clear colchicine, so more colchicine stays in your system. That raises the risk of colchicine side effects, which can include nausea, vomiting, diarrhea, muscle pain or weakness, and, in serious cases, problems with blood counts or organ function.

The risk is highest for people with heart or blood vessel disease taking low-dose colchicine daily, and for people with kidney or liver problems. Don't stop or change either medicine on your own. Tell your pharmacist or doctor you take both, so your care team can choose a safer option or adjust your colchicine dose and watch you closely.

Mechanism: Lapatinib inhibits -mediated colchicine efflux, increasing colchicine exposure ( and ) and the risk of toxicity. Colchicine is not a , so higher exposure means greater toxicity. Colchicine has a , so modest increases matter.

  • Severity on file: . Evidence: probable. Onset: unspecified.
  • Contraindicated: with P-gp in patients with established atherosclerotic disease or multiple CV risk factors taking colchicine 0.5 mg daily (fatal toxicity reported at therapeutic doses), and for gout prophylaxis or treatment in or impairment.
  • Management: use an alternative to the interacting drug, hold colchicine during use, or, if is unavoidable, reduce the colchicine dose. See the colchicine monograph dose adjustment guidance for other populations and regimens.
  • Monitor: symptoms, myotoxicity (myalgia, weakness), and cytopenias.

See the 7 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Lapatinib and Colchicine Interact

The likely mechanism

of -mediated colchicine efflux transport

In short: Lapatinib slows P-glycoprotein, a pump that moves colchicine out of cells, so more colchicine can stay in the body.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Raises Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Lapatinib and Colchicine Interaction

Your care team has a few ways to manage this, depending on your situation and why you take colchicine.

  • Choose an alternative to one of the medicines.
  • Pause colchicine while you are taking lapatinib.
  • If both are truly needed, lower your colchicine dose, which may need to be adjusted and individualized by your care team, who may monitor you more closely.

Keep taking your medicines as prescribed until you hear otherwise. Tell your pharmacist or prescriber about any heart disease, kidney problems, or liver problems. Report diarrhea, vomiting, muscle pain or weakness, or unusual bruising or infections promptly.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Lapatinib or Colchicine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

4 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    A systematic review and classification of the effects of P-glycoprotein inhibitors and inducers in humans, using digoxin, fexofenadine, and dabigatran as probe drugs

    A systematic review of 151 studies examined how and affect the concentration time profile of P-gp . It identified rifampin as a drug with short-term inhibitory effects and time-dependent inductive effects.

    Rifampicin first acts as a P-gp , raising the area under the curve ratio (AUCR) of the probe substrates digoxin (1.31 to 1.46) and dabigatran (2.08 to 2.22). After multiple doses, however, the AUCR was reduced, ranging from 0.68 to 1 for digoxin and from 0.33 to 0.59 for dabigatran.4

  2. Report 2 · Study title

    Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies

    A review article describing the effect of on P-gp exposure found rifampin to be the most potent P-gp , with an average reduction in substrate exposure of 20% to 67%. Only studies in which rifampin administration was staggered relative to the P-gp substrate were included, since rifampin is a mixed /inducer of P-gp.

    Giving rifampin during the phase of the P-gp substrate may cause intestinal , which confounds the assessment of P-gp . Rifampin lowered the of orally administered substrates by 19% to 69.5%, while did not change, suggesting that the effect of rifampin on the P-gp substrate is predominately due to P-gp induction in the intestine, with minimal impact on renal P-gp.5

  3. Report 3 · Study title

    Prescribing information: GLOPERBA oral solution, colchicine oral solution

    In a study (N=19 to 21), of carvedilol phosphate (a ) did not affect the of colchicine, but the geometric mean ratio of colchicine (0 to last) was 118% (90% CI, 112% to 124%). Patients took carvedilol 20 mg daily on Days 11 to 12, then 40 mg daily on Days 13 to 17, and received colchicine 0.6 mg on Day 17. These results should not be extrapolated to other P-gp , because colchicine is a known P-gp and case reports have been published of colchicine toxicity with coadministration of P-gp inhibitors (ie, cyclosporine).6

  4. Report 4 · Study title

    Prescribing information: MITIGARE oral capsules, colchicine oral capsules

    In a study of healthy volunteers, of colchicine with propafenone (a ) 225 mg twice daily for 5 days produced no changes in systemic colchicine levels. These results should nonetheless not be extrapolated to other P-gp , since colchicine is a known P-gp and case reports have been published of colchicine toxicity with coadministration of P-gp inhibitors such as cyclosporine.7

Lapatinib and Colchicine: Common Questions

How serious is the Lapatinib and Colchicine interaction?

It is rated . These should generally not be used together.

How is the Lapatinib and Colchicine interaction managed?

Your care team has a few ways to manage this, depending on your situation and why you take colchicine. Choose an alternative to one of the medicines. Pause colchicine while you are taking lapatinib. If both are truly needed, lower your colchicine dose, which may need to be adjusted and individualized by your care team, who may monitor you more closely. Keep taking your medicines as prescribed unti… Management is individual — always follow your own care team's guidance.

Who is at higher risk from the Lapatinib and Colchicine interaction?

The interaction record names these groups as more likely to be affected:

  • People with liver problems
  • People with heart disease or heart failure

If this describes you, tell your pharmacist or prescriber.

Is there an alternative to taking Lapatinib with Colchicine?

Choose an alternative to one of the medicines.

Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Lapatinib and Colchicine Interaction

Ask in your own words about taking Lapatinib and Colchicine together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (7)

  1. Product Information: LODOCO(R) oral tablets, colchicine oral tablets. AGEPHA Pharma USA, LLC (per FDA), Parsippany, NJ, 2023. DailyMed
  2. Product Information: COLCRYS oral tablets, colchicine oral tablets. Takeda Pharmaceuticals America Inc (per FDA), Deerfield, IL, 2020. DailyMed
  3. Hansten PD, Tan MS, Horn JR, et al: Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf 2023; 46(3):223-242. PubMed
  4. Coumau C & Csajka C: A systematic review and classification of the effects of P-glycoprotein inhibitors and inducers in humans, using digoxin, fexofenadine, and dabigatran as probe drugs. Clin Pharmacokinet 2025; 64(6):849-863. DOI
  5. Elmeliegy M, Vourvahis M, Guo C, et al: Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 2020; 59(6):699-714. PubMed
  6. Product Information: GLOPERBA(R) oral solution, colchicine oral solution. Romeg Therapeutics LLC (per FDA), Woburn, MA, 2019. DailyMed
  7. Product Information: MITIGARE(R) oral capsules, colchicine oral capsules. Hikma Specialty USA Inc (per FDA), Columbus, OH, 2024. DailyMed
Was this write-up helpful?

Other Serious Interactions of Lapatinib and Colchicine

Also serious with Lapatinib

Also serious with Colchicine

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Lapatinib

With Colchicine

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together. This interaction.
  • Major Potentially serious — often needs a change or close monitoring.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.